new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)





Similar
Filing Names

Xencor Inc
Xencor Inc_20100107
  

Xencor Inc patents

Recent patent applications related to Xencor Inc. Xencor Inc is listed as an Agent/Assignee. Note: Xencor Inc may have other listings under different names/spellings. We're not affiliated with Xencor Inc, we're just tracking patents.

ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "X" | Xencor Inc-related inventors




Date Xencor Inc patents (updated weekly) - BOOKMARK this page
03/23/17Heterodimeric antibodies to cd3 x cd123
03/23/17Heterodimeric antibodies to cd3 x cd123
03/02/17Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
12/08/16Trispecific antibodies
12/08/16Heterodimeric antibodies that bind cd3 and tumor antigens
12/01/16Optimized fc variants and methods for their generation
12/01/16Optimized fc variants and methods for their generation
11/24/16Optimized fc variants
11/03/16Optimized fc variants and methods for their generation
10/20/16Optimized fc variants
09/15/16Novel ctla4-ig immunoadhesins
08/11/16Heterodimeric antibodies that bind cd3 and tumor antigens
07/28/16Heterodimeric antibodies that bind cd3 and cd38
06/23/16Heterodimeric antibodies including binding to cd8
06/23/16Fc variants with altered binding to fcrn
05/05/16Methods and compositions for inhibiting cd32b expressing cells
03/10/16Antibodies with modified isoelectric points and immunofiltering
03/03/16Rapid clearance of antigen complexes using novel antibodies
11/05/15Optimized fc variants
08/27/15Complement component c5 antibodies
08/20/15Fc variants with increased affinity for fcyriic
07/09/15Fc variants with altered binding to fcrn
06/04/15Fc variants with altered binding to fcrn
05/21/15Novel compositions and methods for treating ige-mediated disorders
04/09/15Anti-glypican-3 antibody
04/09/15Fc variants with altered binding to fcrn
04/02/15Novel compositions and methods for treating ige-mediated disorders
03/19/15Optimized fc variants and methods for their generation
02/05/15Methods and compositions for inhibiting cd32b expressing cells
02/05/15Methods and compositions for inhibiting cd32b expressing cells
01/29/15Optimized fc variants
01/29/15Optimized fc variants
01/08/15Optimized fc variants
01/08/15Optimized fc variants
12/25/14Optimized fc variants and methods for their generation
12/18/14Novel heterodimeric proteins
12/18/14Optimized fc variants and methods for their generation
12/04/14Methods of purifying heterodimeric proteins using immunoglobulin class switching
10/30/14Novel heterodimeric proteins
10/09/14Optimized anti-cd3 variable regions
10/02/14Fc variants that improve fcrn binding and/or increase antibody half-life
10/02/14Heterodimeric proteins
10/02/14Novel heterodimeric proteins
10/02/14Targeting regulatory t cells with heterodimeric proteins
09/25/14Novel heterodimeric proteins
09/04/14Antibodies with modified isoelectric points
07/31/14Rapid clearance of antigen complexes using novel antibodies
07/24/14Optimized antibodies that target hm1.24
06/12/14Engineered immunoglobulins with extended in vivo half-life
04/24/14Optimized antibodies that target cd19
04/24/14Novel ctla4-ig immunoadhesins
03/27/14Optimized antibodies that target cd19
03/13/14Optimized fc variants
02/27/14Fc variants that extend antibody half-life
11/28/13Methods and compositions for inhibiting cd32b expressing cells
11/14/13Optimized fc variants
10/17/13Optimized fc variants
10/03/13Optimized fc variants
09/19/13Optimized fc variants and methods for their generation
08/15/13Optimized fc variants
08/15/13Optimized fc variants
08/08/13Novel immunoglobulins insertions, deletions, and substitutions
08/08/13Novel compositions and methods for treating ige-mediated disorders
08/08/13Novel compositions and methods for treating ige-mediated disorders
07/11/13Novel compositions and methods for treating ige-mediated disorders
Patent Packs
07/04/13Method for purifying antibodies
06/20/13Optimized fc variants and methods for their generation
06/20/13Optimized fc variants and methods for their generation
05/16/13Antibody variants with enhanced complement activity
03/07/13Optimized fc variants and methods for their generation
12/20/12Methods and compositions for inhibiting cd32b expressing cells
10/11/12Optimized fc variants
09/13/12Optimized fc variants and methods for their generation
09/06/12Novel immunoglobulin insertions, deletions, and substitutions
06/21/12Methods and compositions for inhibiting cd32b expressing cells
06/21/12Methods and compositions for inhibiting cd32b expressing cells
06/14/12Methods and compositions for inhibiting cd32b expressing cells
05/24/12Fc variants that extend antibody half-life
04/12/12Fc variants with altered binding to fcrn
02/02/12Antibodies with modified isoelectric points
Patent Packs
01/19/12Optimized anti-cd30 antibodies
11/24/11Novel ctla4-ig immunoadhesins
10/13/11Fc variants with optimized properties
09/29/11Antibody variants with enhanced complement activity
09/29/11Methods of generating variant proteins with increased host string content and compositions thereof
08/04/11Immunoprotection of therapeutic moieties using enhanced fc regions
05/12/11Fc variants with altered binding to fcrn
03/17/11Immunoglobulin variants outside the fc region
03/03/11Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
01/27/11Optimized fc variants
12/16/10Igg immunoglobulin variants with optimized effector function
12/09/10Optimized proteins that target ep-cam
10/28/10Optimized antibodies that target cd19
09/30/10Modified fc molecules
09/16/10Fc variants with altered binding to fcrn
09/16/10Fc variants with altered binding to fcrn
09/16/10Fc variants with altered binding to fcrn
09/16/10Fc variants with altered binding to fcrn
09/16/10Fc variants with altered binding to fcrn
09/02/10Pharmaceutical compositions for the treatment of tnf-alpha related disorders
08/12/10Fc variants with altered binding to fcrn
07/29/10Methods of generating variant proteins with increased host string content
04/29/10Optimized antibodies that target hm1.24
04/01/10Novel compositions and methods for treating ige-mediated disorders
01/07/10Human equivalent monoclonal antibodies engineered from nonhuman variable regions
08/27/09Optimized fc variants and methods for their generation
08/27/09Optimized fc variants and methods for their generation
06/04/09Optimized fc variants and methods for their generation
05/28/09Methods and compositions for inhibiting cd32b expressing cells
04/09/09Optimized fc variants and methods for their generation
Social Network Patent Pack
03/26/09Optimized fc variants and methods for their generation
03/12/09Optimized fc variants and methods for their generation
03/12/09Optimized fc variants and methods for their generation
02/26/09Optimized fc variants
02/26/09Novel immunoglobulin insertions, deletions and substitutions
01/07/10Human equivalent monoclonal antibodies engineered from nonhuman variable regions







ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Xencor Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Xencor Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###




';